Which statement is true regarding somatropin?

Somatropin is a recombinant form of human growth hormone that is utilized to treat growth hormone deficiencies and certain conditions leading to short stature in children. One notable aspect of somatropin therapy is its interactions with insulin; it can affect glucose metabolism, leading to alterations in insulin requirements for patients who are diabetic or at risk for diabetes. This interaction is significant as it underscores the need for careful monitoring of blood glucose levels in individuals receiving somatropin.

Additionally, prolonged use of somatropin can accelerate growth in bone and soft tissues, which may lead to a condition known as acromegaly if growth hormone levels become excessively high. Acromegaly is characterized by abnormal growth of hands, feet, and facial features due to excess growth hormone in adulthood.

This statement highlights important safety and efficacy considerations when using somatropin. It is critical for healthcare providers to understand these interactions and potential side effects to manage treatment safely and effectively. Thus, recognizing drug interactions with insulin and monitoring for signs of acromegaly is essential in the therapeutic use of somatropin.